Clearmind Medicine Inc. (CMND) Key Metrics
CMND valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $3.2M
- Enterprise value
- −$11.3M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.46
CMND key metrics, FY2017–FY2025
Fiscal year ended October 31, 2025 · U.S. dollarsCMND returns How much profit the business earns on the capital it uses.
CMND financial health Debt, liquidity and how easily interest is covered.
CMND valuation history
CMND returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CMND debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CMND price vs earnings per share
CMND key metrics
FY2017–FY2025| FY2025 | FY2017 | |
|---|---|---|
| Valuation | ||
| Market capitalization | $404.7M | — |
| Enterprise value | $400.9M | — |
| Price / book | 339.3 | — |
| Earnings yield | −1.0% | — |
| Free cash flow yield | −1.2% | — |
| Share price at fiscal year-end | $2,547.20 | — |
| Per share | ||
| Revenue per share | $0.00 | — |
| Earnings per share | −$24.28 | — |
| Operating cash flow per share | −$29.80 | — |
| Free cash flow per share | −$29.80 | — |
| Cash per share | $35.16 | — |
| Book value per share | $7.51 | — |
| Tangible book value per share | $6.89 | — |
| Capex per share | $0.00 | — |
| Debt per share | $11.20 | — |
| Shares outstanding | 159K | — |
| Returns & profitability | ||
| Return on equity (ROE) | −323.4% | −13.2% |
| Return on assets (ROA) | −63.4% | −6.5% |
| Return on tangible assets | −64.4% | −6.5% |
| Financial health | ||
| Total debt | $1.8M | — |
| Cash & short-term investments | $5.6M | $79,860 |
| Net debt | −$3.8M | −$79,860 |
| Debt / equity | 1.49 | — |
| Debt / assets | 0.29 | — |
| Current ratio | 1.22 | 1.68 |
| Quick ratio | 1.22 | 1.68 |
| Interest coverage | -290.1 | — |
| Working capital | $1.1M | $35,004 |
| Invested capital | −$2.6M | −$30,497 |
| Tangible asset value | $1.1M | $49,363 |
| Net current asset value | $1.1M | $35,004 |
| Graham net-net per share | $5.90 | — |
| Capital allocation | ||
| Capex / depreciation | 0.00 | — |
| Efficiency | ||
| Days payables outstanding | 5,043.5 | — |
| Receivables turnover | 0.00 | 0.00 |
| Payables turnover | 0.07 | — |
| Asset turnover | 0.00 | 0.00 |
| Average receivables | $322,282 | $289 |
| Average payables | $682,099 | $832 |
| Intangibles / total assets | 1.6% | 0.0% |
Computed from CMND's annual financial statements (latest annual report filed January 20, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CMND valuation and financial ratios
Clearmind Medicine earned a return on equity of −323.4% in fiscal 2025. It ended the year with $1.8 million of debt and $5.6 million in cash and short-term investments, a net cash position of $3.8 million.
See the CMND income statement, the CMND chart for price history, or the CMND stock overview for the latest quote and news.
CMND key metrics FAQ
What is Clearmind Medicine's return on equity?
Clearmind Medicine's return on equity (ROE) was −323.4% in fiscal 2025: net income of -$3.9 million on average shareholders' equity of $0.6 million.
How much debt does Clearmind Medicine have?
Clearmind Medicine had total debt of $1.8 million at the end of fiscal 2025, a debt-to-equity ratio of 1.49 and more cash than debt.
What is Clearmind Medicine's free cash flow yield?
Clearmind Medicine generated -$4.7 million of free cash flow in fiscal 2025, a free cash flow yield of −1.2% on its market value at year-end ($404.7 million).
What is Clearmind Medicine's current ratio?
Clearmind Medicine's current ratio was 1.22 at the end of fiscal 2025: current assets were 1.22 times current liabilities.